Skip to main content
BLLNBillionToOne, Inc.Hold5.9·$95.50+0.24%

BillionToOne (BLLN) Q2 2026 earnings — TrendMatrix coverage

BEAT+124.3% vs estimateEPS $0.36 vs $0.16 estVerdict Buy (Wait)Hold

Reported

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure

Event detail · Q2 2026

Key numbers

Reported EPS
$0.36
Estimate
$0.16
Surprise
+124.3%
Revenue (period 2026-06-30)
$109.4M
Score at report (before → after)
5.65.5/10

Revenue source: xbrl.

Report record · Q2 2026

How the report landed

BillionToOne (BLLN) beat the $0.16 estimate with diluted EPS of $0.36 — a large 124.3% upside surprise. TrendMatrix's engine moved from Buy (Wait) (5.6/10) to Hold at 5.5/10 after the report — the engine's score fell despite the beat.

Current read · as of 2026-08-23

Where TrendMatrix's rating stands now

TrendMatrix currently rates BLLN Hold at 5.9/10.

2 of the last 3 quarters beat the estimate; this quarter's +124.3% surprise compares with a +194.2% four-quarter average. Next scheduled report: 2026-11-05.

What supports the rating

  • Strong growth profile
  • Wide economic moat

What argues against it

  • Concentration risk — Customer: third-party payors
  • Thin upside margin: 9.6%
  • Expensive valuation

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current engine read

The levels TrendMatrix's engine tracks

Current price
$95.50
Price target
$104.15
Stop
$88.38
Upside to target
+9.1%
Reward-to-risk
0.6:1

The stock trades at 133.8× trailing but 71.5× forward earnings — consensus estimates already build in a substantial earnings recovery.

Risk check: RSI 28 — a level conventionally read as oversold.

Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.

Healthcare context

BLLN at TrendMatrix's latest read

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry
Diagnostics & Research
Market cap
$4.48B
P/E (fwd)
71.5
P/E (ttm)
133.8
52-week range
$61.96$150.44
Off 52-week high
36.5%
RSI (14)
28
Volume vs avg
0.70×
Score today
5.9/10

Earnings figures are sourced from TrendMatrix’s pipeline (EPS: existing earnings extraction; revenue: SEC XBRL company facts where available, yfinance-provisional otherwise). Not a buy/sell rating, a price target, or investment advice — see the current verdict on the stock’s main page for TrendMatrix’s live read.

Home Stocks BLLN Earnings Q2 2026 earnings